logo
Share SHARE
FONT-SIZE Plus   Neg

Threshold Pharma Says FDA Granted Orphan Drug Designation For TH-302

Threshold Pharmaceuticals, Inc. (THLD) announced that the US Food and Drug Administration, or FDA, has granted orphan drug designation for TH-302, a hypoxia-targeted drug, for treating soft tissue sarcoma.

Barry Selick, chief executive officer of Threshold Pharma, stated, "Following our announcement on March 16 regarding the receipt of orphan drug designation in the EU, we are pleased to also have US orphan designation in place. The results of our Phase 2 study (TH-CR-403) in soft tissue sarcoma are certainly supportive of a pivotal trial underway in this difficult to treat cancer."

The company further noted that it is conducting a pivotal Phase 3 study (TH-CR-406) in soft tissue sarcoma comparing TH-302 in combination with doxorubicin against single agent doxorubicin.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
ConAgra Foods Inc. (CAG) reported a net income attributable to the company for the fourth quarter ended May 29, 2016 that declined 43.8 percent from last year. Adjusted earnings per share from continuing operations decreased 5% from the prior year. The comparable earnings per share decline reflected... Another busy month on the FDA calendar has gone by but not without its fair share of hurrahs and heartaches. This is not unexpected, given the uncertainties characterizing drug development and approval processes, which in turn manifest as volatility in stocks belonging to the biotech space. German sporting goods giant Adidas Group (ADDYY.PK, ADDDF.PK) extended its long-term relationship with rapper and fashion designer Kanye West, launching a new line of Yeezy brand products for all genders, the company stated. adidas + Kanye West offers Yeezy branded footwear, apparel and accessories for all genders. Under the deal, West will join with adidas team to lead the development...
comments powered by Disqus
Follow RTT